ABL1 is altered in 0.3% of myelofibrosis patients [2].

ABL1 is an inclusion eligibility criterion in 7 clinical trials for myelofibrosis, of which 3 are open and 4 are closed. Of the trials that contain ABL1 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 3 are phase 2 (2 open) [3].

AFF1 is an inclusion eligibility criterion in 21 clinical trials for myelofibrosis, of which 16 are open and 5 are closed. Of the trials that contain AFF1 status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (4 open), and 3 are phase 3 (3 open) [3].

ASXL1 is altered in 21.69% of myelofibrosis patients [2].

ASXL1 is an inclusion eligibility criterion in 2 clinical trials for myelofibrosis, of which 1 is open and 1 is closed. Of the trials that contain ASXL1 status and myelofibrosis as inclusion criteria, 2 are phase 2 (1 open) [3].

BCR is an inclusion eligibility criterion in 7 clinical trials for myelofibrosis, of which 3 are open and 4 are closed. Of the trials that contain BCR status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 3 are phase 2 (2 open) [3].

CALR is altered in 17.08% of myelofibrosis patients [2].

CALR is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains CALR status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and myelofibrosis as inclusion criteria, 1 is phase 1 (0 open) [3].

DEK is an inclusion eligibility criterion in 6 clinical trials for myelofibrosis, of which 2 are open and 4 are closed. Of the trials that contain DEK status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 2 are phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 20 clinical trials for myelofibrosis, of which 15 are open and 5 are closed. Of the trials that contain ELL status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (3 open), and 3 are phase 3 (3 open) [3].

EZH2 is altered in 7.83% of myelofibrosis patients [2].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

FLT3 is altered in 0.6% of myelofibrosis patients [2].

FLT3 is an inclusion eligibility criterion in 7 clinical trials for myelofibrosis, of which 3 are open and 4 are closed. Of the trials that contain FLT3 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 3 are phase 2 (2 open) [3].

IDH1 is altered in 1.51% of myelofibrosis patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

IDH2 is altered in 2.41% of myelofibrosis patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

IGH is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains IGH status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

IKZF1 is an inclusion eligibility criterion in 2 clinical trials for myelofibrosis, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 status and myelofibrosis as inclusion criteria, 2 are phase 2 (1 open) [3].

JAK2 is altered in 51.2% of myelofibrosis patients [2].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

KIT is altered in 0.6% of myelofibrosis patients [2].

KIT is an inclusion eligibility criterion in 2 clinical trials for myelofibrosis, of which 1 is open and 1 is closed. Of the trials that contain KIT status and myelofibrosis as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 21 clinical trials for myelofibrosis, of which 16 are open and 5 are closed. Of the trials that contain KMT2A status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (4 open), and 3 are phase 3 (3 open) [3].

MAF is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains MAF status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

MAFB is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains MAFB status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

MECOM is an inclusion eligibility criterion in 21 clinical trials for myelofibrosis, of which 16 are open and 5 are closed. Of the trials that contain MECOM status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (4 open), and 3 are phase 3 (3 open) [3].

MLF1 is an inclusion eligibility criterion in 5 clinical trials for myelofibrosis, of which 3 are open and 2 are closed. Of the trials that contain MLF1 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), and 2 are phase 2 (2 open) [3].

MLLT1 is an inclusion eligibility criterion in 20 clinical trials for myelofibrosis, of which 15 are open and 5 are closed. Of the trials that contain MLLT1 status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (3 open), and 3 are phase 3 (3 open) [3].

MLLT10 is an inclusion eligibility criterion in 20 clinical trials for myelofibrosis, of which 15 are open and 5 are closed. Of the trials that contain MLLT10 status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (3 open), and 3 are phase 3 (3 open) [3].

MLLT3 is an inclusion eligibility criterion in 20 clinical trials for myelofibrosis, of which 15 are open and 5 are closed. Of the trials that contain MLLT3 status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (3 open), and 3 are phase 3 (3 open) [3].

MLLT4 is an inclusion eligibility criterion in 20 clinical trials for myelofibrosis, of which 15 are open and 5 are closed. Of the trials that contain MLLT4 status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (3 open), and 3 are phase 3 (3 open) [3].

MPL is altered in 8.73% of myelofibrosis patients [2].

MPL is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains MPL status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and myelofibrosis as inclusion criteria, 1 is phase 1 (0 open) [3].

NPM1 is altered in 2.41% of myelofibrosis patients [2].

NPM1 is an inclusion eligibility criterion in 5 clinical trials for myelofibrosis, of which 3 are open and 2 are closed. Of the trials that contain NPM1 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), and 2 are phase 2 (2 open) [3].

NRIP3 is an inclusion eligibility criterion in 20 clinical trials for myelofibrosis, of which 15 are open and 5 are closed. Of the trials that contain NRIP3 status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (3 open), and 3 are phase 3 (3 open) [3].

NUP214 is an inclusion eligibility criterion in 6 clinical trials for myelofibrosis, of which 2 are open and 4 are closed. Of the trials that contain NUP214 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 2 are phase 2 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 5 clinical trials for myelofibrosis, of which 2 are open and 3 are closed. Of the trials that contain PBX1 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), and 2 are phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 21 clinical trials for myelofibrosis, of which 16 are open and 5 are closed. Of the trials that contain RPN1 status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (4 open), and 3 are phase 3 (3 open) [3].

RUNX1 is altered in 3.01% of myelofibrosis patients [2].

RUNX1 is an inclusion eligibility criterion in 2 clinical trials for myelofibrosis, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and myelofibrosis as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and myelofibrosis as inclusion criteria, 1 is phase 1 (0 open) [3].

SRSF2 is altered in 6.02% of myelofibrosis patients [2].

SRSF2 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains SRSF2 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [3].

TCF3 is an inclusion eligibility criterion in 5 clinical trials for myelofibrosis, of which 2 are open and 3 are closed. Of the trials that contain TCF3 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), and 2 are phase 2 (1 open) [3].

TP53 is altered in 4.22% of myelofibrosis patients [2].

TP53 is an inclusion eligibility criterion in 6 clinical trials for myelofibrosis, of which 2 are open and 4 are closed. Of the trials that contain TP53 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 2 are phase 2 (1 open) [3].